Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on July 21, 2025, regarding events occurring on June 13, 2025. The filing primarily addresses the appointment of a new Senior Vice President and Chief Financial Officer (CFO) and the departure of the incumbent CFO.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- New CFO Base Salary: 81,000 New Israeli Shekels per month (approximately $24,066).
- Stock Option Grant: 597,990 shares of common stock.
- Option Exercise Price: $1.45 per share.
- Option Vesting: 10-year term, vesting over three years in 12 equal quarterly increments.
- Change of Control Bonus: One-time bonus equal to 12 months of salary upon certain change of control transactions.
Material Changes
The primary material change is the leadership transition in the finance function:
- Departure: Eyal Rubin resigned as Vice President and Chief Financial Officer, effective August 24, 2025, to pursue other opportunities. He will remain available for transition support until October 2025.
- Appointment: Gilad Mamlok was appointed as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025.
- Agreement Date: The Employment Agreement governing the new CFO's role was dated June 13, 2025.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding the company's business strategy or market conditions. No specific risks or contingencies related to financial performance are disclosed in this report. The document notes that the Employment Agreement is terminable by the Company on 180 days' written notice and by the executive on 90 days' written notice.
Investor Verification Checklist
- Verify the transition timeline between Eyal Rubin and Gilad Mamlok to ensure continuity of financial reporting.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific performance metrics tied to the discretionary bonus.
- Confirm the impact of the 597,990 stock option grant on potential dilution and the current share price relative to the $1.45 exercise price.
- Monitor future filings for the first financial report prepared under the new CFO's tenure.